bremelanotide

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Stem definition	Drug id	CAS RN
melanocortin receptor agonists; peptides and glycopeptides	5329	189691-06-3

Stem definition

Drug id

CAS RN

melanocortin receptor agonists; peptides and glycopeptides

5329

189691-06-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: bremelanotide bremelanotide acetate vyleesi PT-141	Bremelanotide is a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. The mechanism by which VYLEESI improves HSDD in women is unknown. The MC1R is expressed on melanocytes; binding at this receptor leads to melanin expression and increased pigmentation Molecular weight: 1025.18 Formula: C50H68N14O10 CLOGP: -1.79 LIPINSKI: 3 HAC: 24 HDO: 13 TPSA: 378.97 ALOGS: -4.73 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

bremelanotide
bremelanotide acetate
vyleesi
PT-141

Bremelanotide is a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. The mechanism by which VYLEESI improves HSDD in women is unknown. The MC1R is expressed on melanocytes; binding at this receptor leads to melanin expression and increased pigmentation

Molecular weight: 1025.18
Formula: C50H68N14O10
CLOGP: -1.79
LIPINSKI: 3
HAC: 24
HDO: 13
TPSA: 378.97
ALOGS: -4.73
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-0.585		High	0.80
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.611		High	0.80
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.342	10^-6 cm/s	High	0.80
dh-clint	Dog hepatocyte intrinsic clearance	1.303	uL/min/10^6 cells	High	0.80
dppb	Dog plasma protein binding (% unbound)	81.330	%	High	0.80
fcs-ppb	Fetal calf serum protein binding (% unbound)	44.670	%	High	0.80
herg	hERG pIC50	4.588	pIC50	High	0.80
hh-clint	Human hepatocyte intrinsic clearance	3.597	uL/min/10^6 cells	High	0.80
hlm-clint	Human liver microsomal intrinsic clearance	3.141	uL/min/mg protein	High	0.80
hppb	Human plasma protein binding (% unbound)	81.810	%	High	0.80
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PRKDC	14
kinase-selectivity-class	AXL,GRK2	2
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.324		High	0.80
mh-clint	Mouse hepatocyte intrinsic clearance	5.117		High	0.80
mppb	Mouse plasma protein binding (% unbound)	68.330		High	0.80
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.242		High	0.80
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	69.120	%	High	0.80
rh-clint	Rat hepatocyte intrinsic clearance	3.508	uL/min/10^6 cells	High	0.80
rh-fuinc	Rat hepatocyte fraction unbound in incubation	76.480	%	High	0.80
rppb	Rat plasma protein binding (% unbound)	67.070	%	High	0.80
solubility-dd	Solubility at pH 7.4 in DMSO	883.080	uM	High	0.80

Property

Description

Value

Unit

Confidence

Similarity

azlogd74

LogD at pH 7.4

-0.585

High

0.80

caco2-efflux

Caco-2 efflux ratio (BA/AB)

0.611

High

0.80

caco2-intrinsic-papp

Caco-2 intrinsic apparent permeability

0.342

10^-6 cm/s

High

0.80

dh-clint

Dog hepatocyte intrinsic clearance

1.303

uL/min/10^6 cells

High

0.80

dppb

Dog plasma protein binding (% unbound)

81.330

High

0.80

fcs-ppb

Fetal calf serum protein binding (% unbound)

44.670

High

0.80

herg

hERG pIC50

4.588

pIC50

High

0.80

hh-clint

Human hepatocyte intrinsic clearance

3.597

uL/min/10^6 cells

High

0.80

hlm-clint

Human liver microsomal intrinsic clearance

3.141

uL/min/mg protein

High

0.80

hppb

Human plasma protein binding (% unbound)

81.810

High

0.80

kinase-safety-class

ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PRKDC

kinase-selectivity-class

AXL,GRK2

mdck-mdr1-efflux

MDCK-MDR1 efflux ratio

1.324

High

0.80

mh-clint

Mouse hepatocyte intrinsic clearance

5.117

High

0.80

mppb

Mouse plasma protein binding (% unbound)

68.330

High

0.80

nih-mdck-mdr1-efflux

NIH MDCK-MDR1 efflux ratio

1.242

High

0.80

pfas-class

PFAS structural alert (1 = True, 0 = False)

pppb

Pig plasma protein binding (% unbound)

69.120

High

0.80

rh-clint

Rat hepatocyte intrinsic clearance

3.508

uL/min/10^6 cells

High

0.80

rh-fuinc

Rat hepatocyte fraction unbound in incubation

76.480

High

0.80

rppb

Rat plasma protein binding (% unbound)

67.070

High

0.80

solubility-dd

Solubility at pH 7.4 in DMSO

883.080

High

0.80

Date	Agency	Company	Orphan
June 21, 2019	FDA	AMAG PHARMS INC

Date

Agency

Company

Orphan

June 21, 2019

FDA

AMAG PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nausea	101.10	65.38	45	126	1110271	89518005

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Nausea

101.10

65.38

126

1110271

89518005

Source	Code	Description
ATC	G02CX05	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Other gynecologicals
FDA EPC	N0000194029	Melanocortin Receptor Agonist
FDA MoA	N0000194030	Melanocortin Receptor Agonists

Source

Code

Description

ATC

G02CX05

GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Other gynecologicals

FDA EPC

N0000194029

Melanocortin Receptor Agonist

FDA MoA

N0000194030

Melanocortin Receptor Agonists

Disease	Relation	SNOMED_ID	DOID
Lack or loss of sexual desire	indication	270903007	DOID:13868
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of cardiovascular system	contraindication	49601007	DOID:1287

Disease

Relation

SNOMED_ID

DOID

Lack or loss of sexual desire

indication

270903007

DOID:13868

Hypertensive disorder

contraindication

38341003

DOID:10763

Disorder of cardiovascular system

contraindication

49601007

DOID:1287

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.28	acidic
pKa2	12.41	acidic
pKa3	12.76	acidic
pKa4	13.11	acidic
pKa5	13.39	acidic
pKa6	13.66	acidic
pKa7	8.36	Basic
pKa8	7.73	Basic

Dissociation level

Dissociation constant

Type (acidic/basic)

pKa1

3.28

acidic

pKa2

12.41

acidic

pKa3

12.76

acidic

pKa4

13.11

acidic

pKa5

13.39

acidic

pKa6

13.66

acidic

pKa7

8.36

Basic

pKa8

7.73

Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	VYLEESI (AUTOINJECTOR)	COSETTE	N210557	June 21, 2019	RX	SOLUTION	SUBCUTANEOUS	10286034	Nov. 5, 2033	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	VYLEESI (AUTOINJECTOR)	COSETTE	N210557	June 21, 2019	RX	SOLUTION	SUBCUTANEOUS	9352013	Nov. 5, 2033	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	VYLEESI (AUTOINJECTOR)	COSETTE	N210557	June 21, 2019	RX	SOLUTION	SUBCUTANEOUS	9700592	Nov. 5, 2033	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	VYLEESI (AUTOINJECTOR)	COSETTE	N210557	June 21, 2019	RX	SOLUTION	SUBCUTANEOUS	11590209	April 29, 2041	TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH

Formulation strength

Trade name

Applicant

Application number

Approval date

Type

Dose form

Route

Patent number

Patent expiration date

Patent use

EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)

VYLEESI (AUTOINJECTOR)

COSETTE

N210557

June 21, 2019

SOLUTION

SUBCUTANEOUS

10286034

Nov. 5, 2033

TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)

VYLEESI (AUTOINJECTOR)

COSETTE

N210557

June 21, 2019

SOLUTION

SUBCUTANEOUS

9352013

Nov. 5, 2033

TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)

VYLEESI (AUTOINJECTOR)

COSETTE

N210557

June 21, 2019

SOLUTION

SUBCUTANEOUS

9700592

Nov. 5, 2033

TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)

VYLEESI (AUTOINJECTOR)

COSETTE

N210557

June 21, 2019

SOLUTION

SUBCUTANEOUS

11590209

April 29, 2041

TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Melanocortin receptor 4	GPCR	P32245	MC4R_HUMAN	AGONIST	Kd	8	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Melanocortin receptor 5	GPCR	P33032	MC5R_HUMAN	AGONIST	Ki	7.77	CHEMBL
Melanocortin receptor 3	GPCR	P41968	MC3R_HUMAN	AGONIST	EC50	8.62	CHEMBL
Melanocyte-stimulating hormone receptor	GPCR	Q01726	MSHR_HUMAN	AGONIST	EC50	10.02	CHEMBL
Adrenocorticotropic hormone receptor	GPCR	Q01718	ACTHR_HUMAN	AGONIST			DRUG LABEL

Target

Class

Pharos

UniProt

Action

Type

Activity value
(-log[M])

Mechanism
action

Bioact source

MoA source

Melanocortin receptor 4

GPCR

P32245

MC4R_HUMAN

AGONIST

SCIENTIFIC LITERATURE

Melanocortin receptor 5

GPCR

P33032

MC5R_HUMAN

AGONIST

7.77

CHEMBL

Melanocortin receptor 3

GPCR

P41968

MC3R_HUMAN

AGONIST

EC50

8.62

CHEMBL

Melanocyte-stimulating hormone receptor

GPCR

Q01726

MSHR_HUMAN

AGONIST

EC50

10.02

CHEMBL

Adrenocorticotropic hormone receptor

GPCR

Q01718

ACTHR_HUMAN

AGONIST

DRUG LABEL

External reference:

ID	Source
6Y24O4F92S	UNII
1607799-13-2	SECONDARY_CAS_RN
4038620	VANDF
C1721339	UMLSCUI
CHEMBL2070241	ChEMBL_ID
9941379	PUBCHEM_CID
DB11653	DRUGBANK_ID
CHEMBL4297533	ChEMBL_ID
D06569	KEGG_DRUG
8737	INN_ID
C476721	MESH_SUPPLEMENTAL_RECORD_UI
10408	IUPHAR_LIGAND_ID
427418003	SNOMEDCT_US
788500001	SNOMEDCT_US
CHEBI:757011	CHEBI
37138	MMSL
d09322	MMSL
018059	NDDF
018060	NDDF
2176311	RXNORM
6Y24O4F92S	INXIGHT DRUGS

Source

6Y24O4F92S

UNII

1607799-13-2

SECONDARY_CAS_RN

4038620

VANDF

C1721339

UMLSCUI

CHEMBL2070241

ChEMBL_ID

9941379